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COVID Vaccine Hesitancy Statistics
• National Statistics as of December 2020, based on Kaiser Family Foundation’s Vaccine 
tracker3:
• 27% of the public remains vaccine hesitant, saying they probably or definitely would
not get a COVID-19 vaccine even if it were available for free and deemed safe by 
scientists
• Vaccine hesitancy is highest among Republicans (42%), those aged 30-49 (36%), and 
rural residents (35%)
• 35% of Black adults say they definitely or probably would not get vaccinated, as do 
one third of those who say they have been deemed essential workers (33%) and 
three in ten (29%) of those who work in a health care delivery setting 
• Reasons for hesitancy worries are due to possible side effects (59% cite this as a 
major reason), lack of trust in the government to ensure the vaccines’ safety and 
effectiveness (55%), concerns that the vaccine is too new (53%), and concerns over 
the role of politics in the development process (51%)
• These statistics indicate a grave need for education over the efficacy and safety behind 
mRNA vaccines
Public Health Costs of COVID Vaccination
• Based on data from the Kaiser Family Foundation7, Operation Warp Speed 
and government funding is estimated at 10 billion dollars for COVID-19 
vaccine research, development, and distribution
• Access to COVID-19 vaccines would be greatly enhanced if available at no-
cost to individuals or covered by insurance
• The federal government has taken steps to address this issue, with advance 
purchasing of millions of doses of COVID-19 vaccines 
• Legislative requirements have been passed to provide no-cost COVID-19 
vaccines under private insurance, Medicaid, and Medicare 
• Limitations and gaps remain - individuals may still face cost and barriers to 
access for vaccination (Schwartz, Karen.) 
Community Perspective
• Two interviews were conducted with local healthcare providers in 
Brookfield, CT
• Both physicians expressed serious concern of COVID-19 vaccine 
hesitancy in local community due to the rural setting of Brookfield
• Recent meeting with healthcare providers at Brookfield Family 
practice cited additional concern for hesitancy among black patients 
in surrounding community 
• Distribution and access to vaccines remain a huge question 
• Patient advocacy and education are potential solutions to address 
problem
Intervention and Methodology
• Intervention: Educational handout was created to explain mRNA 
vaccine technology, efficacy, and safety in lay terms for the general 
public
• Methodology: Educational handout will be provided to patients in 
clinic to address questions and concerns about the COVID-19 vaccine
• References for the handout clearly defined so that patients can 
further read about the topic
• The goal is to help educate patients on the science behind mRNA 
vaccines and hopefully reduce hesitancy about the vaccine in the 
local Brookfield community
Results 
• Handout presented to Brookfield Family practice providers
• Administrators plan on distributing handout throughout clinic for 
patient education
• “Extremely pertinent and should be very helpful for patients who are 
vaccine hesitant” - Primary Care Physician 
• “I have concerns about vaccination hesitancy, especially among the 
black community. Educational handouts, like this one, can help 
reduce concerns and make a significant difference going forward” –
Primary Care Physician 
Evaluation of effectiveness and limitations
• Initial review of the handout by providers at Brookfield Family Practice were 
positive
• The team seemed enthusiastic to distribute the handout to patients who had 
questions regarding the efficacy and safety of COVID-19 vaccines
• To evaluate for effectiveness of the handout:
• An initial survey would be created that would assess a patient’s overall hesitancy towards 
the COVID-19 vaccine and reasons for their hesitancy 
• A survey after reading the handout would evaluate patient understanding of mRNA vaccines, 
and assess whether a patient’s hesitancy has changed or whether they are more willing to 
receive a vaccine
• Implementation of a pre- and post-survey could not be accomplished during this 
rotation, but would provide data to measure whether education on vaccines 
affects hesitancy 
• One limitation for this handout is the lack of data on long term efficacy and safety
Recommendations for future 
interventions/projects
• Recommendations for future projects involving COVID-19 vaccination 
would be to implement a quantitative assessment to examine 
whether an educational handout could impact hesitancy
• A pre-and-post survey would be one possible quantitative 
measurement
• Another potential future project would be to create an updated
version of an educational handout on COVID-19 vaccines with more 
data on long-term efficacy and safety
• This potential idea would be important if there is a need for further 
vaccination against COVID-19 in the future
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